C WorldWide Group Holding A S increased its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 6.7% during the second quarter, Holdings Channel reports. The fund owned 105,048 shares of the specialty pharmaceutical company’s stock after buying an additional 6,583 shares during the period. C WorldWide Group Holding A S’s holdings in Jazz Pharmaceuticals PLC were worth $16,335,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in JAZZ. US Bancorp DE boosted its stake in shares of Jazz Pharmaceuticals PLC by 94.4% in the second quarter. US Bancorp DE now owns 758 shares of the specialty pharmaceutical company’s stock worth $118,000 after buying an additional 368 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares in the last quarter. World Asset Management Inc acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $205,000. Janney Montgomery Scott LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC during the second quarter worth approximately $211,000. Finally, Private Advisor Group LLC acquired a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter worth approximately $215,000. 86.43% of the stock is owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals PLC (JAZZ) opened at 143.66 on Friday. The company’s 50 day moving average is $155.38 and its 200-day moving average is $146.54. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The company has a market cap of $8.63 billion, a price-to-earnings ratio of 21.98 and a beta of 1.10.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. The business had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. During the same period in the previous year, the company earned $2.67 EPS. Jazz Pharmaceuticals PLC’s quarterly revenue was up 3.5% compared to the same quarter last year. On average, analysts expect that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current fiscal year.
A number of analysts have commented on JAZZ shares. Wells Fargo & Company reaffirmed an “outperform” rating and set a $177.00 target price (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday. BidaskClub cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Thursday, August 3rd. Zacks Investment Research cut shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $182.00 target price on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Finally, Vetr raised shares of Jazz Pharmaceuticals PLC from a “hold” rating to a “buy” rating and set a $151.11 target price for the company in a report on Tuesday, June 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the stock. Jazz Pharmaceuticals PLC presently has an average rating of “Buy” and an average price target of $182.72.
In other news, EVP Suzanne Sawochka Hooper sold 4,580 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $160.00, for a total transaction of $732,800.00. Following the transaction, the executive vice president now owns 32,322 shares of the company’s stock, valued at approximately $5,171,520. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Rick E. Winningham sold 5,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $150.00, for a total transaction of $750,000.00. Following the transaction, the director now directly owns 10,391 shares in the company, valued at approximately $1,558,650. The disclosure for this sale can be found here. Insiders have sold 10,600 shares of company stock valued at $1,641,720 in the last ninety days. Insiders own 4.30% of the company’s stock.
About Jazz Pharmaceuticals PLC
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
What are top analysts saying about Jazz Pharmaceuticals PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Jazz Pharmaceuticals PLC and related companies.